



(43) International Publication Date 10 April 2003 (10.04.2003)

(51) International Patent Classification7:

(10) International Publication Number WO 03/029296 A1 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK. LR. LS. LT. LU. LV. MA. MD. MG. MK. MN. MW. MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SL

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,

KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,

(84) Designated States (regional): ARIPO patent (GH, GM,

- C12N 5/20, A61K 39/395, A61P 37/06, 35/00
- (21) International Application Number: PCT/US01/30849
- (22) International Filing Date: 2 October 2001 (02.10.2001)
- (25) Filing Language:

English

C07K 16/28.

(26) Publication Language:

English

- (71) Applicant (for all designated States except US): CHI-RON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).
- TG) Published:

ZA, ZW.

with international search report

(72) Inventors; and (75) Inventors/Applicants (for US only): CHU, Keting [US/US]; 2017 Easton Drive, Burlingame, CA 94010

(US). WANG, Changyu [CN/US]; 3101 Carlson Boulevard #4, El Cerrito, CA 94530 (US). YOSHIHARA, Corrine [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). DONNELLY, John, J. [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: ALEXANDER, Lisa; Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608-2916 et al. (US).

(54) Title: HUMAN ANTI-CD40 ANTIBODIES

(57) Abstract: Human antibodies capable of binding CD40 are disclosed, wherein the antibodies act as antagonists of CD40-directed activities of B cells, but have no or minimal ability to induce B cell proliferation. The antibodies are useful for treating diseases mediated by CD40-expressing cells, such as those diseases characterized by B cell activation, as well as cancer of B-cell lineage, including Non-Hodgkin's Lymphoma.